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Introduction
Ulcerative colitis (UC) and Crohn’s disease (CD) 
represent the two major clinically defined forms of 
inflammatory bowel disease (IBD) that may affect 
the whole gastrointestinal tract and the colonic 
mucosa, respectively, and are associated with an 
increased risk of developing colon cancer.1,2 Even 
though widespread, IBD is more common in devel-
oped countries, with the highest incidence rates and 
prevalence registered in North America and Europe. 
However, a substantial variation in the epidemiol-
ogy of IBD has been lately observed with an alarm-
ing rise in prevalence in previously reported 
low-incidence areas, such as Asia, further pointing 
out the urgent need of new pharmacological 
approaches in the management of these diseases.
Usually, therapies for IBD include chronic 
administration of glucocorticosteroids and sul-
fasalazine derivatives. However, these drugs are 
not always effective and cannot be used for long-
term maintenance.3 In fact, steroids are useful in 
the short-term treatment of acute flares, but they 
may induce a number of systemic adverse reac-
tions during prolonged therapy.4,5 Sulfasalazine 
and its derivative 5-aminosalicylic acid (5-ASA) 
are effective only in mild-to-moderate phases of 
the disease and in preventing relapses.4–7 The intro-
duction of monoclonal anti-tumor necrosis 
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factor-alpha (TNFα) antibodies (Infliximab and 
Adalimumab) in the therapy of IBD has radically 
changed their management, since these drugs are 
effective both in controlling moderate-to-severe 
forms of UC and CD and providing an efficient 
prevention of their relapses.8 However, the long-
term safety concerns of these drugs (i.e. the possi-
bility to allow the developing of aggressive form of 
cancer, particularly leukemia and lymphoma9), 
together with the high costs, limit the ordinary use 
of these therapeutics. Moreover, a poor response to 
anti-TNFα therapy has been observed in some 
forms of UC and CD.10 For these reasons, there is 
an urgent need for novel effective drugs, with man-
ageable side toxicity and low costs for patients. In 
this perspective, the identification and characteri-
zation of new therapeutic targets for the develop-
ment of innovative anti-IBD drugs appear to be 
crucial. The etiology of IBD has been extensively 
studied and several efforts have been made aiming 
at a better understanding of the pathophysiological 
mechanisms underlying the disease. Different 
studies have demonstrated the involvement of 
some risk factors including infectious agents, 
viruses and bacteria, autoimmune response, food 
allergies, hereditary factors, and co-morbid stress-
ing conditions.11,12 Generally, CD and UC have 
been univocally identified as autoimmune patholo-
gies and the mucosal macrophages and lympho-
cytes infiltration has been considered as the main 
responsible for the chronic inflammation, occur-
ring in the gut mucosa. Severe dysfunction of the 
mucosal immune system has been thus described 
to play an important role in the pathogenesis of 
IBD.13,14 In general, a wide range of inflammatory 
cells in the gut, such as mucosal CD4+ T cells, are 
thought to play a central role in both the induction 
and the persistence of chronic inflammation by 
producing pro-inflammatory cytokines.15 Several 
studies have demonstrated that the levels of T 
helper 1 (Th1)-related cytokines (e.g. TNFα, inter-
feron gamma (IFN)-γ, interleukin (IL)-12), as well 
as the concentration of other cytokines (e.g. 
IL-17A, IL-21, IL-23), are increased in the 
inflamed mucosa of these patients when compared 
to normal subjects.16–20 Pro-inﬂammatory cytokines 
may profoundly affect intestinal mucosal homeo-
stasis by inducing chronic inflammatory changes, 
including T cell and macrophage proliferation, 
expression of adhesion molecules and chemokines, 
and secretion of other pro-inflammatory cytokines 
that perpetuate, in turn, the chronic inflammation 
in the gut.19,20
From mucosal inflammation concept to the 
enteric-driven neuroinflammation concept
In recent years, it has become clear that the mucosal 
immune system alone may not account for all the 
aspects of IBD pathogenesis and pursuit of new 
players in CD and UC pathophysiology led to 
investigate the involvement of the enteric nervous 
system (ENS) in intestinal inflammation, enlarging 
the concept of inflammation to neuro-inflamma-
tion in IBD.
Although in patients with IBD morphological 
abnormalities of the ENS have been consistently 
described, only in the last decade have recent stud-
ies highlighted the changes occurring in both 
enteric neurons and enteric glial cells during intes-
tinal inflammation.21–24
The ENS takes part to the peripheral nervous 
system and it is located within the wall of the gas-
trointestinal tract. It has been considered the “brain 
of the gut” since, independently from the central 
nervous system (CNS), it coordinates many aspects 
of digestive functions such as motility, blood flow, 
and immune/inflammatory processes.25 Many fea-
tures of digestive function are guided by the ENS, 
a complex network of neurons and glia that works 
independently from the central nervous system. 
The ENS originates from the neural crest, which 
invades, proliferates, and migrates within the intes-
tinal wall until the whole bowel is colonized with 
enteric neural crest-derived cells (ENCDCs). Due 
to different factors and morphogens, the ENCDCs 
develop further, differentiating into glia and neu-
ronal sub-types, interplaying to form a functional 
nervous system.26 Histologically, the ENS is organ-
ized in two major ganglionated plexuses, the myen-
teric (Auerbach’s) and the submucosal (Meissner’s 
and Henle’s) plexus (Figure 1a). These ganglia 
contain neuron cell bodies and are interconnected 
by bundles of nerve processes. The myenteric 
plexus is located between the longitudinal and cir-
cular muscle throughout the gut, from the esopha-
gus to the rectum. It mainly innervates the 
muscolaris externa and controls intestinal motility. 
The sub-mucosal plexus, lying between the mucosa 
and the circular muscle, is involved in the regula-
tion of bowel secretion, especially in the small 
intestine where it is most located. A number of 
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morphological and functional distinct neurons are 
located in both plexuses, including primary affer-
ent neurons, sensitive to chemical and mechanical 
stimuli, interneurons, and motor neurons. Most of 
the enteric neurons involved in motor functions are 
located in the myenteric plexus with some primary 
afferent neurons located in submucosal plexus.27.
Though not fully understood, the neuroinflam-
matory process occurring during IBD refers to 
several structural and functional abnormalities 
occurring in the ENS. In these conditions both 
macroscopic changes (hypertrophy and hyperpla-
sia of nerve bundles and ganglia) and neurotrans-
mitter release adaptations in the ENS are commonly 
observed.22 In patients with IBD, morphological 
changes occurring in the ENS, ranging from the 
alteration of submucosal plexus structure to the 
retraction of neuronal fibers and the appearance of 
neuromatous lesions, are observed.23
Moreover, although the exact mechanism(s) at 
the basis of such alteration has/have not been fully 
understood, it is commonly accepted that the 
increased apoptosis of enteric neurons and EGC is 
closely correlated to several functional distur-
bances observed in IBD patients, such as gut dys-
motility and increased sensory perception.21–23
Enteric glia: The beautiful and the bad weather 
in the gut
Enteric glial cells (EGC), the phenotypical equiva-
lent of astrocytes into the CNS, are small cells with 
a star-like shape and are believed to represent the 
most abundant cells in the ENS;28 EGCs are for 
these reasons considered as active partners in ENS 
function.29 They display dynamic responses to 
neuronal inputs and may take part into the release 
of neuro-active factors. At present, EGCs of human 
gut are usually identified by the expression of the 
S100B and GFAP protein, as well as by the expres-
sion of more recently recognized markers such as 
Sox 10.30–33 EGCs surround enteric neuron bodies 
and axons,34 as well as intestinal blood vessels35 
while their processes extend into the mucosa.36 
Despite the previous assumption that EGCs may 
serve as mechanical support for enteric neurons, 
nowadays the knowledge on these cells is consist-
ently expanded. Functionally, EGCs are believed 
to be responsible for many of peripheral neurons 
functions trough the release of a variety of soluble 
factors.37 Under physiological conditions, major 
histocompatibility complex class I (MHC I) mole-
cules are constitutively expressed by EGCs, while 
MHC class II molecules are almost undetecta-
ble.38,39 It has become increasing clear that EGCs 
play a pivotal role in the regulation of intestinal 
homeostasis, leading to a more multifaceted and 
comprehensive knowledge of these cells.40 Beside 
their trophic and cytoprotective functions toward 
enteric neurons, enteric glial cells play a key role in 
Figure 1a. Schematic representation of the gut wall. 
Myenteric plexus innervates the muscularis externa and 
controls the intestinal motility; the submucosal plexus 
innervates the submucosal blood vessels and is basically 
involved in the control of the intestinal secretory functions.
Figure 1b. GFAP immunofluorescence staining in the enteric 
nervous system. The figure shows the localization of myenteric 
plexus and submucosal plexus networks in mice intestine 
indicated by green arrows. White arrows indicate the close 
proximity of enteric glial cell processes with epithelial cells in 
the mucosa. Magnification 100×.
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the intestinal epithelial barrier homeostasis and 
integrity.41 The intestinal barrier regulates the pas-
sage of the intestinal contents, preventing the dif-
fusion of microbes and other pathogens (including 
viruses) through the mucosa. EGCs are in close 
proximity of gut epithelial cells and similarly to 
their counterparts in the CNS, they may affect 
intestinal permeability through the release of sev-
eral mediators, directly controlling epithelial bar-
rier functions.42 Among the different EGC-related 
mediators, glial-derived neurotrophic factor 
(GDNF) plays a fundamental role in the preserva-
tion of mucosal integrity under the enteric glia sur-
veillance. GDNF indeed exerts anti-inflammatory 
effects via a dual mechanism; on one hand, it inhib-
its EGCs apoptosis in an autocrine manner; on the 
other, via a paracrine mechanism, it lowers the 
level of pro-inflammatory cytokines, such as IL-1β 
and TNFα, that significantly increases during IBD 
and gut infections.43 Recently it has been shown 
that EGCs can assure the integrity of the intestinal 
barrier through the release of S-nitrosoglutathione 
(GSNO).44 The effect of this metabolite is associ-
ated with the overexpression of tight junction asso-
ciated-proteins, for example zonula occludens-1 
(ZO-1) and occludin, that in turn prevents the 
intestinal barrier breakdown during an inflamma-
tory insult, linking with actin cytoskeleton ring and 
myosin light chain (MLC). Thus, EGCs play 
important functions in the maintenance of ENS 
homeostasis, but they may also proliferate and be 
activated in response to injury and inflammation, 
undergoing reactive gliosis (entero-gliosis).45,46,47 
In these conditions, EGCs activity is profoundly 
altered and, following injury and inflammation, 
these activated cells undergo a dynamic process 
associated with an increased proliferation and a 
pro-inflammatory phenotype.45,47,48 Enteroglial 
activation is characterized by the over-release of 
neurotrophins, growth factors, and cytokines that, 
in turn, recruit infiltrating immune cells such as 
macrophages, neutrophils, and mast cells in the 
colonic mucosa.47–49 During the onset and perpetu-
ation of the inflammatory state of the mucosa, 
EGCs control of mucosal integrity is markedly 
altered.50 These results are in line with several 
studies50–53 showing that ECGs can regulate the 
expression of genes responsible for adhesion, dif-
ferentiation, and proliferation of epithelial cells,54 
further confirming the importance of enteric glia in 
the epithelial barrier homeostasis. In the context of 
signaling molecules released by ECGs, the produc-
tion of transforming growth factor-β1 (TGF- β1) 
and vascular endothelial growth factor (VEGF) 
might be involved in the onset and metastasis of 
colon cancer during IBD, thanks to their effects on 
the epithelial cells proliferation and formation of 
new blood vessels.55 Very interestingly, different 
evidences let hypothesize that EGCs act as primum 
movens in triggering and amplifying the inflamma-
tory cascade during chronic inflammatory insult of 
the gut.45,46,56 An intriguing correlation between 
the degree of enteric gliosis and severity of gut 
inflammation has been also reported and an inti-
mate interaction between EGCs and the mucosal 
immune system has been observed.50,57
EGC drive neuroinflammation in IBD: The role of 
S100B protein and its partnership with nitric oxide
In recent years, it has been assumed that EGCs are 
involved in the chronic mucosal inflammation in 
UC; and many EGC-related signaling molecules 
thought to orchestrate such neuroinflammatory 
cross-talk are under extensive investigation.58,59 
The S100B protein, one of the typical markers of 
EGC, seems to play a crucial role in IBD.45 S100B 
is the homodimer of subunit and belongs to a 
Ca2+-Zn2+ binding proteins super-family that com-
prises more than 20 proteins.35 In the gut, S100B 
protein is constitutively expressed by EGCs45 while 
other members of S100 family, such as S100A8, 
S100A9, and S100A12 are expressed only under 
inflammatory conditions by phagocytes and intesti-
nal epithelial cells.45,60 The role exerted by S100B 
in gut inflammation has been only recently high-
lighted.45,61 S100B is a pivotal signaling molecule 
that participates at the onset and progression of the 
inflammatory status, as it coordinates a wide range 
of signal activation pathways, directly correlated 
with the severity of tissue damage.61 This is high-
lighted by the observation that rectal specimens 
from early diagnosed UC patients show an increased 
S100B protein expression (Figure 2a).45
The upregulation of S100B runs in parallel with 
an increased production of NO via the stimulation 
of iNOS protein expression. This is a very impor-
tant point since a large group of studies pointed out 
that in UC patients an abnormal NO secretion by 
pro-inflammatory cytokines has been observed due 
to the progressive activation of iNOS protein.62,63 
In more detail, researches performed by comparing 
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patients with UC and healthy subjects demon-
strated that rectal specimens from UC patients 
show an increased immunoreactivity for S100B 
protein and a significantly enhanced protein secre-
tion and expression.56 This upregulation cannot be 
considered a mere epiphenomenon because it is 
related to the specific activation of inducible NO 
synthase (iNOS) protein leading to an increase of 
NO level. Thus, S100B upregulation has a promi-
nent role during ulcerative colitis. The correlation 
between S100B upregulation and NO production is 
very interesting since, as previously described, UC 
is characterized by abnormal mucosal NO produc-
tion.63 EGCs ability of modulating NO levels via 
S100B release has been confirmed also in absence 
of a chronic inflammatory scenario. In fact, the 
administration of micromolar concentration of 
exogenous S100B is able to induce a concentra-
tion-dependent activation of iNOS expression and 
a subsequent enhanced NO production, in rectal 
mucosa of healthy subjects.56 In line with this it has 
been suggested that EGCs modulate the 
NO-dependent inflammatory response through the 
release of S100B within the intestinal milieu and 
let hypothesize that S100B release might be a first 
step in the onset of inflammation.64 Once released, 
S100B may accumulate at the RAGE (Receptor for 
Advanced Glycation End products) site in micro-
molar concentrations.65,66 Such interaction leads 
then to mitogen-activated protein kinase (MAPK) 
phosphorylation and consequent nuclear factor-
kappaB (NF-κB) activation which, in turn, induces 
the transcription of different cytokines, such as 
iNOS protein, IL-1B, TNFα (Figure 2b).67,68 
Although the mechanisms by which EGCs and 
their signaling molecule S100B may coordinate 
such a complex inflammatory scenario is just ini-
tially conceived; more recently, a close relation-
ship with toll-like receptors (TLRs) activation has 
been proposed.61 In fact, the direct interaction 
between S100B and RAGE receptors during colitis 
has to be considered an initial event triggering the 
activation of a specific downstream pathway 
involved in the maintenance of a persistent entero-
glial-sustained inflammation in the human gut. 
RAGE is also involved in the enteroglial TLRs 
signaling network, and it has become clear that, 
since EGCs express different TLR subtypes 
depending upon their pathophysiological func-
tions;69 these cells may be involved in a wider net-
work of neuro-immunological pathways. 
Supporting this hypothesis, a specific S100B/
RAGE/TLR-4 axis during gut inflammation has 
thus been observed as a pivotal molecular mecha-
nism sustaining EGC activation during UC.61
Figure 2a. S100B protein in ulcerative colitis (UC). 
Immunofluorescence analysis showing the upregulation of 
S100B protein in UC versus healthy specimen. Arrows indicate 
S100B protein expression spots in both in myenteric plexus 
and in mucosa. Magnification 100×.
Figure 2b. Schematic representation of the S100B pro-
inflammatory signaling. The linkage between S-100B and RAGE 
is able to increase the production of NO and other pro-
inflammatory cytokines via the activation of NFκB.
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Conclusions and perspectives: Could 
we consider EGC targeting as a novel 
approach to develop anti-IBD drugs?
The urgent need of new pharmacological 
approaches that may enlarge the tools against IBD, 
as well as a better knowledge on new molecular 
players involved in the triggering and perpetuation 
of inflammation in the gut is a very important chal-
lenge for pharmacologists and gastroenterologists. 
This review highlighted the importance of EGCs as 
fundamental cell type within the ENS that partici-
pate to the modulation of inflammatory responses 
in the human gut. ENS alterations, featured by 
apoptotic bodies of neurons and glia,70 especially 
in submucosal plexi, is commonly observed in 
human IBD, and it has been postulated to play a 
fundamental role in the in the occurrence of disor-
ders of intestinal motility and or secretion.21,23
EGCs trigger and promote chronic inflamma-
tion in the intestinal mucosa since these cells over-
release S100B that in turn determinates NO 
production. Such detrimental loop is responsible 
for a substantial recruitment of other target cells, 
including immune cells. In fact, EGC-derived 
S100B is able to affect peripheral macrophages 
and intestinal mucosal immune cell. A better under-
standing of the molecular mechanisms underlying 
EGC dysfunction, might constitute a new approach 
to increase the efficacy of new enteric-glia oriented 
drugs that may overcome the lack of long-term 
effectiveness of immunosuppressant agents used 
for IBD.
In the next future, molecules capable to selec-
tively target EGC-mediated neuroinflammation, 
might represent a novel approach to develop new 
therapeutic strategies for IBD. In this context, the 
possibility to interfere with the S100B/NO axis 
may pave the way to a significant improvement of 
the actual therapies against UC or CD. To this aim, 
in preclinical studies, we demonstrated that the 
specific inhibition of S100B protein activity with 
pentamidine, an antiprotozoal drug, resulted in a 
marked reduction of EGC-mediated neuroinflam-
mation severity in mice.71 Similar results were 
obtained in vivo in mice and in human UC-deriving 
cultured biopsies with palmitoylethanolamide 
(PEA), an endogenous autacoid local inflamma-
tion antagonism (ALIA)-mide, able to downregu-
late S100B protein expression and to inhibit 
S100B-dependent activation of TLR-4 on enteric 
glia.61 Both pharmacological approaches resulted 
in a significant downregulation of inflammatory 
parameters, and improved significantly the disease 
course through a selective enteroglial-specific tar-
geting, although in a preclinical evidence.
In conclusion, most of the studies on the role of 
enteric glia have been carried out in preclinical ani-
mal models of IBD. Although this might appear as 
a limitative factor due to the unpreventable differ-
ences emerging by the IBD process in vivo and the 
human disease, EGCs powerfully emerge as a very 
intriguing target on which develop selective drugs 
to treat CD and UC.
Acknowledgements
We are grateful to Luisa Seguella for her technical assis-
tance to manuscript preparation.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest 
with respect to the research, authorship, and/or publication 
of this article.
Funding
This research received no specific grant from any funding 
agency in the public, commercial, or not-for-profit sectors.
References
 1. Rhodes JM and Campbell BJ (2002) Inflammation 
and colorectal cancer: IBD-associated and sporadic 
cancer compared. Trends in Molecular Medicine 8: 
10–16.
 2. M’Koma AE (2013) Inflammatory bowel disease: An 
expanding global health problem. Clinical Medicine 
Insights Gastroenterology 6: 33–47.
 3. Fascì-Spurio F, Aratari A, Margagnoni G, et al. (2012) 
Oral beclomethasone dipropionate: A critical review 
of its use in the management of ulcerative colitis and 
Crohn’s disease. Current Clinical Pharmacology 7: 
131–136.
 4. Hanauer SB and Stathopoulos G (1991) Risk-benefit 
assessment of drugs used in the treatment of inflam-
matory bowel disease. Drug Safety 6: 192–219.
 5. Engel MA and Neurath MF (2010) New pathophysio-
logical insights and modern treatment of IBD. Journal 
of Gastroenterology 45: 571–583.
 6. Ham M and Moss AC (2012) Mesalamine in the 
treatment and maintenance of remission of ulcerative 
colitis. Expert Review of Clinical Pharmacology 5(2): 
113–123.
 7. Ford AC, Achkar JP, Khan KJ, et al. (2011) Efficacy 
of 5-aminosalicylates in ulcerative colitis: Systematic 
Capoccia et al. 449
review and meta-analysis. American Journal of 
Gastroenterology 106: 601–616.
 8. Spurio FF, Aratari A, Margagnoni G, et al. (2012) 
Early treatment in Crohn’s disease: Do we have 
enough evidence to reverse the therapeutic pyramid? 
Journal of Gastrointestinal and Liver Diseases 21: 
67–73.
 9. Rosh JR, Gross T, Mamula P, et al. (2007) 
Hepatosplenic T-cell lymphoma in adolescents and 
young adults with Crohn’s disease: A cautionary tale? 
Inflammatory Bowel Diseases 13: 1024–1030.
 10. Guerra I and Bermejo F (2014) Management of 
inflammatory bowel disease in poor responders to inf-
liximab. Clinical and Experimental Gastroenterology 
7: 359–367.
 11. Frolkis A, Dieleman L, Barkema DVM, et al. (2013) 
Environment and the inflammatory bowel diseases. 
Canadian Journal of Gastroenterology 27(3) :e18–e24.
 12. Molodecky NA and Kaplan GG (2010) Environmental 
risk factors for inflammatory bowel disease. 
Gastroenterology & Hepatology 6(5): 339–346.
 13. Pastorelli L, De Salvo C, Mercado JR, et al. (2013) 
Central role of the gut epithelial barrier in the patho-
genesis of chronic intestinal inflammation: Lessons 
learned from animal models and human genetics. 
Frontiers in Immunology 4: 280.
 14. Rescigno M (2011) The intestinal epithelial barrier in 
the control of homeostasis and immunity. Trends in 
Immunology 32: 256–264.
 15. Shih DQ and Targan SR (2008) Immunopathogenesis 
of inflammatory bowel disease. World Journal of 
Gastroenterology 14(3): 390–400.
 16. Nikolaus S, Bauditz J and Gionchetti P. (1998) 
Increased secretion of pro-inflammatory cytokines by 
circulating polymorphonuclear neutrophils and regu-
lation by interleukin 10 during intestinal inflamma-
tion. Gut 42(4): 470–476.
 17. Cobrin GM and Abreu MT (2005) Defects in mucosal 
immunity leading to Crohn’s disease. Immunological 
Reviews 206: 277–295.
 18. Nunes T, Bernardazzi C and de Souza HS (2014) 
Interleukin-33 and inflammatory bowel dis-
eases: Lessons from human studies. Mediators of 
Inflammation 2014: 423957.
 19. Andoh A, Yagi Y, Shioya M, et al. (2008) Mucosal 
cytokine network in inflammatory bowel disease. 
World Journal of Gastroenterology 14(33): 5154–
5161.
 20. Scaldaferri F and Fiocchi C (2007) Inflammatory 
bowel disease: Progress and current concepts of eti-
opathogenesis. Journal of Digestive Diseases 8(4): 
171–178.
 21. Geboes K and Collins S (1998) Structural abnor-
malities of the nervous system in Crohn’s disease and 
ulcerative colitis. Neurogastroenterology and Motility 
10: 189–202.
 22. Lakhan SE and Kirchgessner A (2010) 
Neuroinflammation in inflammatory bowel disease. 
Journal of Neuroinflammation 7: 37.
 23. Villanacci V, Bassotti G, Nascimbeni R, et al. (2008) 
Enteric nervous system abnormalities in inflammatory 
bowel diseases. Neurogastroenterology and Motility 
20(9): 1009–1016.
 24. Bassotti G, Villanacci V, Fisogni S, et al. (2007) 
Enteric glial cells and their role in gastrointestinal 
motor abnormalities: Introducing the neuro-gliopa-
thies. World Journal of Gastroenterology 13(30): 
4035–4041.
 25. Goyal RK and Hirano I (1996) The enteric nervous 
system. New England Journal of Medicine 334(17): 
1106–1115.
 26. Laranjeira C and Pachnis V (2009) Enteric nervous 
system development: Recent progress and future chal-
lenges. Autonomic Neuroscience 151(1): 61–69.
 27. Furness JB and Costa M (1980) Types of nerves in the 
enteric nervous system. Neuroscience 5(1): 1–20.
 28. Gabella G (1981) Ultrastructure of the nerve plexuses 
of the mammalian intestine: The enteric glial cells. 
Neuroscience 6(3): 425–436.
 29. Rühl A, Nasser Y and Sharkey KA (2004) Enteric 
glia. Neurogastroenterology and Motility 16 Suppl 1: 
44–49.
 30. Bjorklund H, Dahl D and Seiger A (1984) 
Neurofilament and glial fibrillary acid protein-related 
immunoreactivity in rodent enteric nervous system. 
Neuroscience 12(1): 277–287.
 31. Ferri GL, Probert L, Cocchia D, et al. (1982) Evidence 
for the presence of S-100 protein in the glial compo-
nent of the human enteric nervous system. Nature 
297(5865): 409–410.
 32. Hoff S, Zeller F, von Weyhern CW, et al. (2008) 
Quantitative assessment of glial cells in the human 
and guinea pig enteric nervous system with an 
anti-Sox8/9/10 antibody. Journal of Comparative 
Neurology 509(4): 356–371.
 33. Jessen KR and Mirsky R (1980) Glial cells in the 
enteric nervous system contain glial fibrillary acidic 
protein. Nature 286(5774): 736–737.
 34. Gershon MD and Rothman TP (1991) Enteric glia. 
Glia 4(2): 195–204.
 35. Liu YA, Chung YC, Pan ST, et al. (2013) 3-D 
imaging, illustration, and quantitation of enteric 
glial network in transparent human colon mucosa. 
Neurogastroenterology and Motility 25(5): e324–338.
 36. Hanani M and Reichenbach A (1994) Morphology 
of horseradish peroxidase (HRP)-injected glial cells 
in the myenteric plexus of the guinea-pig. Cell and 
Tissue Research 278(1): 153–160.
450 International Journal of Immunopathology and Pharmacology 28(4) 
 37. Rühl A (2006) Glial regulation of neuronal plastic-
ity in the gut: Implications for clinicians. Gut 55(5): 
600–602.
 38. Geboes K, Rutgeerts P, Ectors N, et al. (1992) 
Major histocompatibility class II expression on the 
small intestinal nervous system in Crohn’s disease. 
Gastroenterology 103(2): 439–447.
 39. Koretz K, Momburg F, Otto HF, et al. (1987) 
Sequential induction of MHC antigens on autoch-
thonous cells of ileum affected by Crohn’s disease. 
American Journal of Pathology 129(3): 493–502.
 40. Bassotti G, Villanacci V, Antonelli E, et al. (2007) 
Enteric glial cells: New players in gastrointestinal 
motility? Laboratory Investigation 87(7): 628–632.
 41. Yu YB and Li YQ (2014) Enteric glial cells and their 
role in the intestinal epithelial barrier. World Journal 
of Gastroenterology 20(32): 11273–11280.
 42. Savidge TC, Sofroniew MV and Neunlist M (2007) 
Starring roles for astroglia in barrier pathologies of 
gut and brain. Laboratory Investigations 87(8): 731–
736.
 43. Zhang DK, He FQ, Li TK, et al. (2010) Glial-derived 
neurotrophic factor regulates intestinal epithelial bar-
rier function and inflammation and is therapeutic for 
murine colitis. Journal of Pathology 222: 213–222.
 44. Savidge TC, Newman P, Pothoulakis C, et al. (2007) 
Enteric glia regulate intestinal barrier function and 
inflammation via re-lease of S-nitrosoglutathione. 
Gastroenterology 132(4): 1344–1358.
 45. Cirillo C, Sarnelli G, Esposito G, et al. (2011) S100B 
protein in the gut: The evidence for enteroglial sus-
tained intestinal inflammation. World Journal of 
Gastroenterology 17(10): 1261–1266.
 46. Esposito G, Cirillo C, Sarnelli G, et al. (2007) Enteric 
glial-derived S100B protein stimulates nitric oxide 
production in celiac disease. Gastroenterology 133(3): 
918–925.
 47. Burns AJ and Pachnis V (2009) Development of the 
enteric nervous system: Bringing together cells, sig-
nals and genes. Neurogastroenterology and Motility 
21: 100–102.
 48. Von Boyen GB, Steinkamp M, Geerling I, et al. 
(2006) Proinflammatory cytokines induce neuro-
trophic factor expression in enteric glia: A key to the 
regulation of epithelial apoptosis in Crohn’s disease. 
Inflammatory Bowel Diseases 12: 346–354.
 49. Sharkey KA (2015) Emerging roles for enteric glia 
in gastrointestinal disorders. Journal of Clinical 
Investigation 125(3): 918–925.
 50. Cabarrocas J, Savidge TC and Liblau RS (2003) Role 
of enteric glial cells in inflammatory bowel disease. 
Glia 41: 81–93.
 51. Neunlist M, Van Landeghem L, Bourreille A, et al. 
(2008) Neuro-glial crosstalk in inflammatory bowel 
disease. Journal of Internal Medicine 263: 577–583.
 52. Cheadle GA, Costantini TW, Lopez N, et al. (2013) 
Enteric glia cells attenuate cytomix-induced intestinal 
epithelial barrier breakdown. PLoS One 8(7): e69042.
 53. Bach-Ngohou K, Mahé MM, Aubert P, et al. (2010) 
Enteric glia modulate epithelial cell proliferation and 
differentiation through 15-deoxy-Δ12,14-prostaglandin 
J2. Journal of Physiology 588: 2533–2544.
 54. Van Landeghem L, Mahé MM, Teusan R, et al. (2009) 
Regulation of intestinal epithelial cells transcriptome 
by enteric glial cells: Impact on intestinal epithelial 
barrier functions. BMC Genomics 10: 507.
 55. Neunlist MP, Aubert P, Bonnaud S, et al. (2007) 
Enteric glia inhibit intestinal epithelial cell prolif-
eration partly through a TGF-β1-dependent pathway. 
American Journal of Physiology Gastrointestinal and 
Liver Physiology 292(1): G231–241.
 56. Cirillo C, Sarnelli G, Esposito G, et al. (2009) 
Increased mucosal nitric oxide production in ulcera-
tive colitis is mediated in part by the enteroglial 
derived S100B protein. Neurogastroenterology and 
Motility 21(11): e1209–1112.
 57. Cornet A, Savidge TC, Cabarrocas J, et al. (2001) 
Enterocolitis induced by autoimmune targeting of 
enteric glial cells: A possible mechanism in Crohn’s 
disease? Proceedings of the National Academy of 
Sciences of the United States of America 98(23): 
13306–13311.
 58. Von Boyen GBT, Steinkamp M, Reinshagen M, et 
al. (2004) Proinflammatory cytokines increase glial 
fibrillary acidic protein expression in enteric glia. Gut 
53(2): 222–228.
 59. Von Boyen G and Steinkamp M (2010) The role of 
enteric glia in gut inflammation. Neuron Glia Biology 
6(4): 231–236.
 60. Leach ST, Yang Z, Messina I, et al. (2007) Serum and 
mucosal S100 proteins, calprotectin (S100A8/S100A9) 
and S100A12, are elevated at diagnosis in children with 
inflammatory bowel disease. Scandinavian Journal of 
Gastroenterology 42(11): 1321–1331.
 61. Esposito G, Capoccia E, Turco F, et al. (2014) 
Palmitoylethanolamide improves colon inflammation 
through an enteric glia/toll like receptor 4-dependent 
PPAR-α activation. Gut 63(8): 1300–1312.
 62. Linehan JD, Kolios G, Valatas V, et al. (2005) Effect of 
corticosteroids on nitric oxide production in inflamma-
tory bowel disease: Are leukocytes the site of action? 
American Journal of Physiology Gastrointestinal and 
Liver Physiology 288(2): G261–267.
 63. Menchen L, Colon AL, Madrigal JL, et al. (2004) 
Activity of inducible and neuronal nitric oxide syn-
thases in colonic mucosa predicts progression of ulcer-
ative colitis. American Journal of Gastroenterology 
99(9): 1756–1764.
 64. Cirillo C, Sarnelli G, Turco F, et al. (2011) 
Proinflammatory stimuli activates human-derived 
Capoccia et al. 451
enteroglial cells and induces autocrine nitric oxide 
production. Neurogastroenterology and Motility 
23(9): e372–e382.
 65. Donato R (2007) RAGE: A single receptor for several 
ligands and different cellular responses: the case of 
certain S100 proteins. Current Molecular Medicine 
7(9): 711–724.
 66. Schmidt AM, Yan SD, Yan SF, et al. (2001) The mul-
tiligand receptor RAGE as a progression factor ampli-
fying immune and inflammatory responses. Journal 
of Clinical Investigation 108(7): 949–955.
 67. Esposito G, De Filippis D, Cirillo C, et al. (2006) 
The astroglial-derived S100beta protein stimulates 
the expression of nitric oxide synthase in rodent mac-
rophages through p38 MAP kinase activation. Life 
Sciences 78(23): 2707–2715.
 68. Lam AG, Koppal T, Akama KT, et al. (2001) 
Mechanism of glial activation by S100B: Involvement 
of the transcription factor NFkappaB. Neurobiology 
of Aging 22(5): 765–772.
 69. Turco F, Sarnelli G, Cirillo C, et al. (2014) Enteroglial-
derived S100B protein integrates bacteria-induced 
Toll-like receptor signaling in human enteric glial 
cells. Gut 63(1): 105–115.
 70. Bassotti G, Villanacci V, Nascimbeni R, et al. 
(2009) Enteric neuroglial apoptosis in inflammatory 
bowel diseases. Journal of Crohn’s & Colitis 3(4): 
264–270.
 71. Esposito G, Capoccia E, Sarnelli G, et al. (2012) The 
antiprotozoal drug pentamidine ameliorates experi-
mentally induced acute colitis in mice. Journal of 
Neuroinflammation 9: 277.
